Skip to main content

Ex-Alexion, bluebird execs launch VC and manufacturing firm with $150M

The former CEO of Alexion Pharmaceuticals and chief scientific officer at bluebird bio have raised $150 million to launch a new biotech investment and manufacturing firm for cell and gene therapies.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.